$11.12−0.41 (−3.56%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Cellebrite DI (CLBT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~17.9%/yr (FY21→FY25), net margin 16.5%, and free cash flow (~$160.3M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+54.7%) and Capex step-up ($13.2M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲18.6%
475.7
FY21→FY25CAGR +17.9%/yr
Net income ($M)—
78.3
one-off year: see footnoteCAGR +2.3%/yr
Free cash flow ($M)▲29.7%
160.3
capex stepped upCAGR +50.9%/yr
Diluted EPS—
0.31
FY21→FY25CAGR −8.4%/yr
What the receipts whisper · what a headline number hides
Share count
+54.7%
161.5mn → 249.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$13.2M
▲54% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
16¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 82.7% → 84.2%. Net margin 16.5% is above the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | FY25 † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 475,675.0 | 475,675.0 | 401,203.0 | 325,110.0 | 270,651.0 | 246,246.0 | ▲18.6% | +17.9% |
Cost of revenue | 75,172.0 | 75,172.0 | 62,593.0 | 53,231.0 | 50,746.0 | 42,557.0 | ▲20.1% | +15.3% |
Gross profit | 400,503.0 | 400,503.0 | 338,610.0 | 271,879.0 | 219,905.0 | 203,689.0 | ▲18.3% | +18.4% |
Research & development | 113,877.0 | 113,877.0 | 98,415.0 | 84,386.0 | 80,620.0 | 65,541.0 | ▲15.7% | +14.8% |
Selling, general & admin | 65,332.0 | 65,332.0 | 50,900.0 | 43,443.0 | 40,854.0 | 47,937.0 | ▲28.4% | +8.0% |
Total operating expenses | 334,023.0 | 334,023.0 | 281,704.0 | 238,642.0 | 218,861.0 | 189,867.0 | ▲18.6% | +15.2% |
Operating incomefeeds ROC rank | 66,480.0 | 66,480.0 | 56,906.0 | 33,237.0 | 1,044.0 | 13,822.0 | ▲16.8% | +48.1% |
Other income, net | 24,198.0 | 24,198.0 | −332,890.0 | −108,800.0 | 119,716.0 | 68,483.0 | — | — |
Pretax income | 90,678.0 | 90,678.0 | −275,984.0 | −75,563.0 | 120,760.0 | 82,305.0 | — | +2.5% |
Income tax | 12,352.0 | 12,352.0 | 7,023.0 | 5,537.0 | −45.0 | 10,909.0 | ▲75.9% | +3.2% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 78,326.0 | 78,326.0 | −283,007.0 | −81,100.0 | 120,805.0 | 71,396.0 | — | +2.3% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.31 | 0.31 | −1.35 | −0.43 | 0.59 | 0.44 | — | −8.4% |
Diluted shares (mn) | 249.90 | 249.90 | 209.47 | 190.15 | 195.39 | 161.54 | ▲19.3% | +11.5% |
| Margins | ||||||||
Gross margin94th pct in Technology | 84.2% | 84.2% | 84.4% | 83.6% | 81.3% | 82.7% | ▼0.2pp | +1.5pp |
Operating margin | 14.0% | 14.0% | 14.2% | 10.2% | 0.4% | 5.6% | ▼0.2pp | +8.4pp |
Net margin69th pct in Technology | 16.5% | 16.5% | −70.5% | −24.9% | 44.6% | 29.0% | ▲87.0pp | −12.5pp |
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.FY21 effective tax rate was 13% vs a −0% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was 14% vs a −0% norm for this window, likely a one-time item; see the filing.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-03 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Cellebrite DI's revenue last fiscal year?
Cellebrite DI reported revenue of $475.7M in fiscal 2025, up 18.6% from fiscal 2024.
What was Cellebrite DI's net income?
Cellebrite DI reported net income of $78.3M in fiscal 2025, a net margin of 16.5%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

